SGT 53

Drug Profile

SGT 53

Alternative Names: p53-gene-therapy-SynerGene; TfRscFv-Liposome-p53 Complex

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SynerGene Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Apoptosis stimulants; Gene transference; P53 gene stimulants; Tumour suppressor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma; Pancreatic cancer
  • Phase I Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (IV, Infusion)
  • 01 Dec 2016 SynerGene Therapeutics completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease) in USA (IV) (NCT00470613)
  • 31 Dec 2014 SynerGene Therapeutics receives two Phase I SBIR, six Phase I STTR and two Phase II STTR grants for the development of SGT 53 for Solid Tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top